Work

Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy

Year: 2010
Type: article
Abstract: On January 25, the FDA approved liraglutide, a glucagon-like-peptide-1 receptor agonist that can improve glycemic control in adults with type 2 diabetes. Drs. Mary Parks and Curtis Rosebraugh discuss the benefits and potentially serious safety concerns associated with this new therapy.
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2058922633
FWCI: 28.15
Cites: 3
Cited by: 290
Related to: 10